2.84
price up icon2.16%   0.06
after-market After Hours: 2.90 0.06 +2.11%
loading
Palisade Bio Inc stock is traded at $2.84, with a volume of 118.55K. It is up +2.16% in the last 24 hours and down -17.20% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.78
Open:
$2.82
24h Volume:
118.55K
Relative Volume:
1.67
Market Cap:
$4.03M
Revenue:
-
Net Income/Loss:
$-12.30M
P/E Ratio:
-0.4416
EPS:
-6.4313
Net Cash Flow:
$-11.13M
1W Performance:
-16.10%
1M Performance:
-17.20%
6M Performance:
-63.31%
1Y Performance:
-67.07%
1-Day Range:
Value
$2.72
$3.22
1-Week Range:
Value
$2.18
$3.4355
52-Week Range:
Value
$2.18
$22.35

Palisade Bio Inc Stock (PALI) Company Profile

Name
Name
Palisade Bio Inc
Name
Phone
(858) 704-4900
Name
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Name
Employee
9
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PALI's Discussions on Twitter

Palisade Bio Inc Stock (PALI) Latest News

pulisher
Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com

Oct 30, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News

Oct 24, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 12, 2024

Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Palisade Bio receives Health Canada nod for UC drug trial - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance

Oct 10, 2024
pulisher
Oct 08, 2024

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 08, 2024
pulisher
Sep 28, 2024

Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India

Sep 28, 2024
pulisher
Sep 27, 2024

Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online

Sep 26, 2024
pulisher
Sep 25, 2024

PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK

Sep 25, 2024
pulisher
Sep 25, 2024

PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Klea Holding Evaluates Generous Takeover Offer - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily

Sep 23, 2024
pulisher
Sep 22, 2024

Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com

Sep 22, 2024
pulisher
Sep 22, 2024

116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst

Sep 21, 2024
pulisher
Sep 20, 2024

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus

Sep 19, 2024
pulisher
Sep 18, 2024

Alaska Air completes acquisition of Hawaiian Airlines - The Seattle Times

Sep 18, 2024
pulisher
Sep 18, 2024

Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World

Sep 18, 2024
pulisher
Sep 16, 2024

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga

Sep 16, 2024
pulisher
Sep 16, 2024

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies - StockTitan

Sep 16, 2024
pulisher
Sep 16, 2024

Palisade Bio Launches New Corporate Branding and Reiterates - GlobeNewswire

Sep 16, 2024
pulisher
Sep 13, 2024

Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga

Sep 13, 2024
pulisher
Sep 11, 2024

Why Palisade Bio Stock Is Soaring Today - MSN

Sep 11, 2024
pulisher
Sep 05, 2024

Palisade Bio advances ulcerative colitis treatment - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire

Sep 05, 2024
pulisher
Sep 05, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification - Yahoo Finance

Sep 05, 2024
pulisher
Sep 03, 2024

Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online

Sep 03, 2024
pulisher
Aug 29, 2024

Palisade Bio (NASDAQ:PALI) Trading 3.2% Higher - Defense World

Aug 29, 2024
pulisher
Aug 21, 2024

Palisade Bio Edges up on Q2 Results - MSN

Aug 21, 2024
pulisher
Aug 21, 2024

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire

Aug 21, 2024
pulisher
Aug 19, 2024

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 19, 2024

Palisade Bio Inc Stock (PALI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Palisade Bio Inc Stock (PALI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Williams Donald Allen
Director
Jun 11 '24
Option Exercise
0.00
340
0
340
Jones Mitchell Lawrence
Chief Medical Officer
May 28 '24
Option Exercise
0.00
4,290
0
4,313
Finley John David
CEO, CFO, Director
May 28 '24
Option Exercise
0.00
7,068
0
14,079
Williams Donald Allen
Director
May 28 '24
Buy
4.86
1,000
4,863
1,000
Finley John David
CEO, CFO, Director
May 24 '24
Buy
4.81
1,000
4,810
8,437
Jones Mitchell Lawrence
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
460
0
880
Finley John David
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
443
0
6,832
Finley John David
CEO, CFO, Director
Mar 11 '24
Option Exercise
0.00
5,558
0
96,849
Neal James R
Director
Feb 09 '24
Option Exercise
0.00
10,920
0
10,920
Csimma Cristina
Director
Feb 08 '24
Option Exercise
0.00
12,800
0
12,862
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):